Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of BOTOX in idiopathic overactive bladder with urinary incontinence
2009-013089-26Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in overactive bladder (OAB), sponsored by Allergan. Primary endpoint: Co-primary efficacy/safety measures. Started Jul 2009; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2009-013089-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013089-26.